5-Fluorouracil (5-FU), in combination with other cytotoxic drugs, is commonly used to treat a variety of cancers. Dihydropyrimidine dehydrogenase (DPD) catalyzes the first catabolic step of the 5-FU degradation pathway, converting 80% of 5-FU to its inactive metabolite. Approximately 0.3% of the population demonstrate complete DPD deficiency, translating to extreme toxicity of 5-FU. Here we present a case of a patient who had a fatal outcome after treatment with 5-FU who was found to have an unknown DPD deficiency discovered at autopsy.
Dihydropyrimidine Dehydrogenase Deficiency, Drug-Related Side Effects and Adverse Reactions, Genetic Testing, Fluorouracil, Pancytopenia
MeulendijksD, CatsA, BeijnenJH, SchellensJH. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity – Ready for clinical practice? Cancer Treat Rev. 2016;50:23-34. [https://doi.org/10.1016/j.ctrv.2016.08.002]. [PMID:27589829]
van KuilenburgABP, HäuslerP, SchalhornA, et al. Evaluation of 5-Fluorouracil pharmacokinetics in cancer patients with a C.1905+1G>A Mutation in DPYD by means of a bayesian limited sampling strategy. Clin Pharmacokinet. 2012;51(3):163-74. [https://doi.org/10.1007/BF03257473]. [PMID:22339448]
Etienne-GrimaldiM-C, BoyerJ-C, BeroudC, et al. New advances in DPYD genotype and risk of severe toxicity under capecitabine. Plos One. 2017;12;(5)1-19.
MeulendijksD, HenricksLM, SonkeGS, et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16(16):1639-50. [https://doi.org/10.1016/S1470-2045(15)00286-7]. [PMID:26603945]